Showing papers in "European Journal of Cancer in 2008"

TL;DR: Cancer prevention and management in Europe is moving in the right direction through the combination of earlier detection, better access to care and improved treatment, especially in the domain of female smoking prevalence and the emerging obesity epidemic.

TL;DR: New evidence strongly suggests that intravenous calcium and magnesium therapy can attenuate the development of oxaliplatin-induced CIPN, without reducing treatment response, and accumulating data suggest that vitamin E may also attenuateThe development of CIPn.

TL;DR: In specific clinical settings regional hyperthermia (RHT) or hyperthermic perfusion has proved its value and deserve a greater focus and investigation in other malignancies.

TL;DR: Prognostic factor analysis shows that stage, age and histological subtype were important predictors of behaviour which may explain differences between CS and LMS, and CS appears to show more kinship to poorly differentiated endometrial carcinomas in behaviour.

TL;DR: The current evidence-base justifies new enthusiasm for the design of complex intervention studies in the management of cancer cachexia and novel biomarkers for patient stratification and more specific techniques for the estimation of muscle mass and physical activity level herald a new era in trial design.

TL;DR: The QLQ-PR25 demonstrates acceptable psychometric properties and clinical validity, and some caution should be used in interpreting the bowel function and side-effects of hormonal therapy scales; results can be reported at the individual item and scale level.

TL;DR: Three mesothelin targeted agents are in various stages of clinical evaluation in patients, including SS1P (CAT-5001) a recombinant immunotoxin targeting Mesothelin, MORAb-009 a chimeric anti-mesothelin monoclonal antibody and CRS-207 a live-attenuated Listeria monocytogenes vector encoding human mesothelins.

TL;DR: Several reasons for the difficult elucidation of new markers will be addressed including the involvement of cellular pathways in tumour biology instead of single genes and interference in disease outcome as a result of anticancer therapies.

TL;DR: The definitions and characteristics of as well as current and evolving therapies for triple-negative and basal-like breast cancer are discussed.

TL;DR: The clinical estimate of survival remains a powerful independent prognostic indicator, often enhanced by experience, but research has only begun to understand the different biases affecting clinicians' estimates.

TL;DR: The evidence suggests that statins do not have short-term effects on cancer risk, and high quality cohort studies with long follow-up are needed to resolve the issue.

TL;DR: The aim was to systematically review the epidemiologic evidence for an association of circulating interleukin-6 (IL-6), an inflammatory cytokine and cancer, and found that cancer patients' IL-6 concentrations were higher than healthy controls' in most studies, but the results of investigations comparing cancer patients and individuals with benign diseases were less consistent.

TL;DR: ILC is a distinct entity of breast cancer that responds well to adjuvant hormonal therapy (HT) with improvement in survival in patients who received HT compared with matched patients with IDC.

TL;DR: The population-based incidence, diagnostic procedures, therapy and survival of thymic epithelial tumours were determined using the Netherlands National Pathological Archives and the Netherlands Cancer Registry.

TL;DR: Although surgery should be the primary treatment for selected patients with MBO, it should not be undertaken routinely in patients known to have poor prognostic criteria for surgical intervention such as intra-abdominal carcinomatosis, poor performance status and massive ascites.

TL;DR: US detects early-stage cancers in women with mammography-negative dense breasts, with higher contribution in women younger than 50 years, than cancers detected on mammography.

TL;DR: Cox regression models of the time to moderate or severe fibrosis were developed on a random set of 1797 patients with and 1827 patients without a boost, and validated in the remaining set, and Nomograms with these factors are proposed to forecast the long-term risk of moderate orsevere fibrosis.

TL;DR: The study suggests that the risk for several cancers increases in subjects affected by metabolic syndrome, and the pharmacological control of the syndrome seems to be inadequate for reducing cancer risk.

TL;DR: Social inequality in the prognosis of most cancers was observed, despite the equal access to health care in Denmark, with poorer relative survival related to fewer advantages, regardless of how they were measured.

TL;DR: The model provides a tool to generate experimental hypothesis to gain insights into the mechanisms of signal transduction associated to the TGF-beta membrane receptor type I and predicts complete inhibition of pSmad and rapid turnover rates.

TL;DR: Tastuzumab, a recombinant monoclonal antibody against the Her2 receptor, is the only FDA-approved targeted agent for treatment of Her2-overexpressing breast cancer, and work has been directed at trying to elucidate the exact mechanism of resistance to trastuzuab and identifying ways to overcome them.

TL;DR: FOXP3-positive Tregs may be a novel marker for identifying high-risk gastric cancer patients and represent an innovative therapeutic target, according to present findings.

TL;DR: It is shown that neutrophil-derived MMP-9 is able to release biologically active VEGF(165) from the ECM of colon cancer cells by the cleavage of heparan sulphates.

TL;DR: The best evidence for the effectiveness of drug treatments is for the haematopoietic agents in anaemic patients undergoing chemotherapy and for methylphenidate in an on-treatment population.

TL;DR: Paclitaxel was found to be an active agent in angiosarcoma of soft tissue in this retrospective analysis and this results need to be confirmed in a prospective randomised phase II study.

TL;DR: Following the treatment schedules allocated by BCLC staging had survival benefits for HCC patients, including surgical resection and transarterial embolisation and conformal radiotherapy.

TL;DR: Palliative care is becoming increasingly recognised as a vital component of cancer care, but requires investment in research, education and services, incorporating appropriate needs assessment and outcome measurements.

TL;DR: Overall, the rigorous investigation of the pharmacology of tamoxifen facilitated tamoxIFen's ubiquitous use for the targeted treatment of breast cancer, chemoprevention and pioneered the exploration of selective oestrogen receptor modulators (SERMs).

TL;DR: The likelihood of receiving radiotherapy was reduced for all sites studied with increasing travel time to the nearest radiotherapy hospital, and lung cancer patients living further from a thoracic surgery hospital were less likely to receive surgery.

TL;DR: Daily therapy with RAD001 plus letrozole is promising: the results suggest anti-tumour activity with no PK interactions, and the overall safety profile of the combination is consistent with that expected for RAD001 monotherapy.